Dr. Tai-An Lin named chief scientific officer at SpringWorks Therapeutics

SpringWorks Therapeutics Inc. (NASDAQ: SWTX), a Stamford-based clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, has appointed Dr. Tai-An Lin as its chief scientific officer.

Lin has more than a quarter-century of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. He joins SpringWorks from Black Diamond Therapeutics, where he was senior vice president of translational science and discovery biology. Earlier in his career, he led the translational biomarker research team and immuno-oncology precision medicine efforts at EMD Serono. He has a Ph.D. in biochemistry from University of Missouri-Columbia and completed postdoctoral research in Molecular Biology and Pharmacology at Washington University in St. Louis.

“Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery into clinical development,” said Saqib Islam, CEO of SpringWorks. “I am delighted to welcome Tai-An to our leadership team and look forward to his contributions as we continue to grow our pipeline on behalf of oncology patients who are in need of transformative new therapies.”